…for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer. In a clinical trial, 32 men with high-risk or very high-risk prostate cancers who were scheduled for prostate cancer surgery were treated with six weekly infusions of enoblituzumab prior to surgery, and were followed for an average of 30 months…

…three sites within the body. Of the estimated 1.3 million men worldwide newly diagnosed with prostate cancer each year, some 20% have metastatic disease, although it’s unclear what percentage of those overall have oligometastatic cancers. Prostate cancer is the third most common cancer and the most common cancer among men in the United States, resulting in about 30,000 deaths annually….

…for prostate cancer. “To me,” she says, “the science story here is the value of keeping your eyes open, because if you do, failures can turn into successes.” That’s because Slusher is not a prostate cancer expert — she is a professor of neurology and vice director of Johns Hopkins Medicine’s Pedersen Brain Science Institute. Slusher’s “science story” goes back…

…benign prostatic hyperplasia and prostatitis diseases, and 31 healthy people with none of these conditions. RNA alone was not sufficient to positively identify the cancer, but addition of a group of disease-specific metabolites provided separation of cancer from other diseases and healthy people. “A simple and noninvasive urine test for prostate cancer would be a significant step forward in diagnosis….

…team conducted the first prospective (temporally correct) study showing that intraprostatic inflammation is associated with an increased risk of prostate cancer in men without an indication for biopsy. The team’s current goals continue to be to identify molecular indicators of prostate cancer risk and progression to lethality, especially molecular factors that may explain the profound racial disparity and to develop…

…that the Prostate Cancer Research Team is most proud of: Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM. A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer…

…cancers — prostate cancer, pancreatic cancer, brain cancer, melanoma, colon cancer, sarcoma and neuroblastoma — tested by us and others grew slower in mice lacking NF-κB p50.” Other Johns Hopkins researchers involved in the study were Rahul Suresh (now with Kite Pharma), David Barakat, Theresa Barberi, Lei Zheng, Elizabeth Jaffee and Kenneth Pienta. The research was supported by a V…

…focus more resources on cancer research models such as genetically engineered mice and 3D balls of human tissue known as “tumoroids” to better evaluate human cancer biology and treatments, and the genetic errors responsible for cancer growth and progress. “It may not be a surprise to scientists that cancer cell lines are genetically inferior to other models, but we were…

…CVD is not uniform across cancers. For example, breast, lung, colorectal and hematological/lymphatic cancers were significantly associated with a higher risk of CVD, whereas prostate cancer was not. The American Cancer Society estimates that there are more than 16.9 million adult survivors of cancer in the U.S. today, and that the number will climb to over 22.1 million by 2030,…

…single mutated copy of MUTYH also affects one’s risk of developing cancer. “We know two missing copies of MUTYH greatly increases the risk of colon cancer, and now it appears that having only one missing copy may lead to a small increased risk of other cancer types,” says the study’s lead author, Channing Paller, M.D., director of prostate cancer clinical…